Clinical Trial Update: Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating an antigen-loaded dendritic cell vaccine for hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Dendritic cell vaccine (antigen-loaded) (dendritic cell vaccine loaded with tumor antigens)

Snippet

Sponsor: Cantonal Hospital of St. Gallen | Conditions: Cancer of the Prostate | Phase 1, Phase 2 | Status: COMPLETED